Prevalence of Major Comorbidities in Chronic Obstructive Pulmonary Disease Caused by Biomass Smoke or Tobacco

Golpe, Rafael; Martín-Robles, Irene; Sanjuán-López, Pilar; Cano-Jiménez, Esteban; Castro‐Añón, Olalla; Mengual-Macenlle, Noemí; Pérez-de-Llano, Luis

doi:10.1159/000472718

Cited by 21 publications

(20 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No other significant association was found between other comorbidities. 15 In contrast, Cheng et al found that allergic diseases (such as allergic rhinitis and bronchial asthma) were significantly more common in biomass induced COPD in comparison to smoking induced COPD, where lung cancer was more common. There was no significant difference in the cardiac comorbidities such as CAD, HF or arrhythmias.…”

Section: Discussionmentioning

confidence: 94%

“…This is similar to the study by Golpe et al who showed that biomass fuel induced COPD has slower decline of FEV1 and different distribution of phenotypes in comparison to smoking induced COPD. 15 Similarly, Cheng et al retrospectively analysed 206 patients with tobacco smokeinduced COPD and 81 cases of biomass smoke-induced COPD. They reported that COPD caused by biomass fuel was more common in females, had dyspnoea as more common symptom, had lower BMI and were in Group B or D according to GOLD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparison of Clinical Profile and Prevalence of Comorbidities Among Biomass and Tobacco Smoke-Induced Copd Patients at a Tertiary Care Centre in North India

Jangpangi¹,

Singh²,

Rawat³

et al. 2018

jemds

View full text Add to dashboard Cite

BACKGROUND Although, smoking is the most common risk factor implicated in the causation of chronic obstructive pulmonary disease (COPD), biomass smoke exposure is an important risk factor, especially in women residing in rural areas of developing countries such as India. Comorbidities are prevalent in patients with COPD because of systemic inflammation. The prevalence of comorbidities among biomass smoke-induced COPD has not been widely studied. Aims and Objectives-To assess whether patients exposed to biomass fuel have similar clinical profile and prevalence of comorbidities as smoker COPD or not. MATERIALS AND METHODSThe clinical characteristics and prevalence of comorbidities were compared between 411 male patients with smoker COPD and 288 female patients with biomass smoke-induced COPD. RESULTSThe patients exposed to biomass fuel were all females, were younger, had higher body mass index (BMI) and had less severe disease (higher values of post bronchodilator (BD) forced expiratory volume in the first second (FEV1 %)). The mean age in smoker COPD was significantly higher than in biomass smoke-induced COPD (p < 0.001). The mean BMI was lower in smoker COPD as compared to that in biomass smoke-induced COPD and this difference was statistically significant (p= 0.042). Coronary artery disease (CAD) (13.86% versus 3.81%, p < 0.0001) and systemic hypertension (HTN) (15.32% versus 3.47%, p < 0.0001) were significantly more common in smoker COPD without any other significant differences. Obstructive sleep apnoea (OSA), lung cancer and anaemia were found to be more common in biomass fuel-induced COPD, although not statistically significant. CONCLUSIONCAD and systemic HTN were significantly more prevalent in smoker COPD. KEYWORDSChronic Obstructive Pulmonary Disease, Biomass, Tobacco, Comorbidity. HOW TO CITE THIS ARTICLE: Jangpangi DS, Singh A, Rawat J, et al. A comparison of clinical profile and prevalence of comorbidities among biomass and tobacco smoke-induced COPD patients at a tertiary care centre in North India.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

A Comparison of Clinical Profile and Prevalence of Comorbidities Among Biomass and Tobacco Smoke-Induced Copd Patients at a Tertiary Care Centre in North India

Jangpangi¹,

Singh²,

Rawat³

et al. 2018

jemds

View full text Add to dashboard Cite

show abstract

“…COPD patients are at increased risk for CVD, and studies that improve insight into the underlying pathophysiological mechanisms are warranted [3,[30][31][32]. We hypothesized that platelet-monocyte interaction would be increased in COPD in concurrence with increased platelet activation and platelet hyper-reactivity.…”

Section: Discussionmentioning

confidence: 99%

Increased Platelet-Monocyte Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity

Aleva¹,

Temba

Mast

et al. 2017

Respiration

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is well known for its cardiovascular co-morbidities. Increased platelet-monocyte interaction is found in COPD and may reflect altered platelet function and a potential role for anti-platelet therapy. Objectives: The objectives were to investigate platelet-monocyte interaction, platelet activation and reactivity and plasmatic coagulation in stable COPD. Methods: Platelet-monocyte interaction and platelet activation were determined by flow cytometry in 30 stable COPD patients and 25 controls. Platelet activation was measured by binding of fibrinogen to the activated fibrinogen receptor and platelet P-selectin expression at baseline and after platelet stimulation with platelet agonists. Plasmatic coagulation was measured by D-dimer and thrombin generation. Results: Platelet-monocyte interaction was increased in stable COPD (median fluorescence intensity of platelet CD61 was 19.8 [IQR 14.0-33.2] vs. 10.0 [IQR 8.7-16.7], p = 0.002). In contrast, platelet activation and reactivity, reflected by fibrinogen binding and P-selectin expression, were the same in both groups. Plasma P-selectin and interleukin-6 were increased in COPD (p = 0.01 and p = 0.02, respectively), whereas soluble fibrinogen, D-dimer and thrombin generation were similar. Conclusions: Increased platelet-monocyte interaction was found in the absence of platelet hyper-reactivity and activation of plasmatic coagulation in stable COPD. Future clinical evaluation of the effects of different anti-platelet drugs in COPD is warranted, as anti-platelet therapy may interfere with platelet-monocyte interaction.

show abstract

“…The epidemiological, clinical and socio-economical impact of comorbidities of COPD has been studied by many 1,2 . Importance of comorbidities in COPD increases due to the fact that COPD is projected to be 3 rd leading cause of death in the world by 2030 and 7 th as a burden of disease 3,4 . COPD can progressively affect functions of multiple organs thus several comorbidities prevail in elderly patients.…”

Section: Introductionmentioning

confidence: 99%

Impact of Comorbidities on Chronic Obstructive Pulmonary Disease Patients

Alam

Yuwen

Xinghua

et al. 2019

Chatt Maa Shi Hosp Med Coll J

View full text Add to dashboard Cite

Background: Many studies were conducted on the subject at home and abroad but there is none in Chattogram region of Bangladesh. To unveil the facts and figures on the subject we have conducted the study. Methods: It was a descriptive study conducted in 2017 at different Private Hospitals of Chattogram. Sample size was purposively determined. Data were collected with a pretested checklist. SPSS version 20 was used for data management. Results: Total 1490 patients were studied. Mean age was 45±6.3 years. Comorbidities were found in 924(62%) cases. Leading comorbidities were Diabetes 66%, Diabetes plus Hypertension 47%, Peptic ulcer diseases 36%, Ischaemic heart disease 15% and others 11%. Chronic Obstructive Pulmonary Disease (COPD) patients with comorbidity stayed longer in hospital (14 days versus 8 days). They also paid more than that of patients without comorbidity (USD 1176 versus 353). Conclusion: COPD with comorbidities cost more than COPD without comorbidities. So, focus should be given more to prevent comorbidities as far as possible. Chatt Maa Shi Hosp Med Coll J; Vol.18 (1); Jan 2019; Page 8-9

show abstract

Prevalence of Major Comorbidities in Chronic Obstructive Pulmonary Disease Caused by Biomass Smoke or Tobacco

Cited by 21 publications

References 26 publications

A Comparison of Clinical Profile and Prevalence of Comorbidities Among Biomass and Tobacco Smoke-Induced Copd Patients at a Tertiary Care Centre in North India

A Comparison of Clinical Profile and Prevalence of Comorbidities Among Biomass and Tobacco Smoke-Induced Copd Patients at a Tertiary Care Centre in North India

Increased Platelet-Monocyte Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity

Impact of Comorbidities on Chronic Obstructive Pulmonary Disease Patients

Contact Info

Product

Resources

About